Insulin lispro

Humalog, Admelog and Lyumjev have adult/pediatric diabetes indication wording. Humalog and Admelog pediatric support includes type 1 diabetes ages ≥ 3 plus adult studies; Lyumjev pediatric support includes type 1 ages ≥ 1 plus adult/pediatric evidence. These are product-specific evidence ages, not one interchangeable minimum-age statement for the class.

Subcutaneous injections generally accompany intermediate/long-acting insulin; pump delivery supplies basal and bolus insulin using its programmed regimen. No fixed basal-insulin starting algorithm or universal units/kg prescription is supplied. Protamine premixes (Humalog Mix75/25/Mix50/50), other brands and individualized DKA/critical-care protocols are outside this standalone-product reference.

Inject in abdomen, thigh, upper arm or buttocks; rotate healthy sites and avoid thickened/depressed or amyloid areas. Adjust units using the prescribed mealtime/correction plan, glucose results and clinical circumstances.

Use only a pump whose instructions permit the exact product. U-200 must never be given by pump or IV. Pump users need training and an injectable backup plan.

• Change infusion set/site per the pump manufacturer; replace insulin exposed above37°C. Reservoir maximum is not an infusion-set replacement schedule.
• IV use is only under medical supervision with close glucose and potassium monitoring; dose/rate follows the supervised protocol.

Humalog U-100 may be mixed ONLY with NPH for injection: draw lispro first and inject immediately. Do not mix Humalog U-200, Admelog or Lyumjev with another insulin. Medical-supervised SC dilution differs: Humalog U-100 uses its Sterile Diluent to U-10 or U-50; current Admelog labeling permits equal parts U-100 and sterile0.9% sodium chloride to U-50. Lyumjev has no SC dilution regimen here. Never apply a dilution rule to a pen, pump or different product.

Renal/hepatic impairment increases hypoglycemia risk and may require more frequent adjustment/glucose monitoring, without a fixed eGFR-based formula. Meal/activity changes, acute illness, medicines and switching sites/brands can alter needs. For forgotten Lyumjev mealtime dosing, its label instructs glucose assessment to decide whether a dose is needed and resumption of usual schedule next meal; do not automatically double doses.

Do not administer during hypoglycemia or with hypersensitivity to insulin lispro/the exact Humalog or Admelog ingredients, or insulin lispro-aabc/the exact Lyumjev ingredients.

No boxed warning appears in these selected labels. Severe hypoglycemia, medication errors, anaphylaxis, hypokalemia and pump-related ketoacidosis remain serious labeled risks.

Hypoglycemia, weight gain, edema, local reactions, lipodystrophy/cutaneous amyloidosis and antibodies are reported. Site reactions differ across products/routes; trial rates should not be pooled. Excess insulin causes potentially recurrent hypoglycemia and hypokalemia. Treat a mild low with oral glucose when able to swallow; severe neurologic symptoms need emergency glucagon or IV glucose and observation. Do not give food/drink to an unconscious person.

Published lispro pregnancy studies do not report an association with major birth defects/miscarriage/adverse outcomes, but methodological limitations prevent exclusion of all risk. Poorly controlled diabetes itself poses substantial maternal/fetal risk. Selected labels report insulin/lispro in milk without reported infant adverse reactions; milk-production effects are unknown. Balance maternal need and breastfeeding, with individualized glucose/dose review.

Humalog/Admelog pediatric support includes type 1 age ≥ 3; Lyumjev type 1 age ≥ 1. Product indication wording is broader than those trial ages. Follow specialist meal/monitoring/device education; monitor Lyumjev sites closely, particularly with pediatric pump use. Older adults need careful recognition of lows, functional/device ability and changing comorbidity.

No fixed unit adjustment is supplied. Declining kidney/liver function may reduce requirements and increase lows even when a study shows limited PK change. Increase glucose checks and adjust to clinical response rather than declaring no renal/hepatic effect.

Promotes glucose uptake in muscle/fat and inhibits hepatic glucose production. It also inhibits lipolysis/proteolysis and promotes protein synthesis. Lispro’s absorption is faster than regular human insulin; Lyumjev’s formulation changes early absorption.

Humalog absorption

SC serum peaks ~30–90 minutes in studied doses; onset/duration vary with site, exercise and dose.

Lyumjev absorption

In studied subjects appears in circulation ~1 minute after injection; peak ~57 minutes. These PK observations are not a dosing/redosing instruction.

Lyumjev effect

Clamp duration was dose-dependent (~4.6–7.3 hours at 7–30 units); no single duration applies to every patient.

Elimination

Humalog SC half-life ~1 hour; Lyumjev median IV half-life44 minutes in studied subjects. Product/route PK must not replace glucose monitoring.

• Follow prescribed glucose/CGM plan and clinical glycemic progress; increase checks during regimen, meal/activity, illness or organ-function changes.
• Review low-glucose events/awareness, meal timing, units, injection/infusion sites and device technique.
• Monitor potassium for IV therapy or other risks; monitor weight/edema/HF with TZDs.
• Investigate unexplained hyperglycemia/ketosis promptly, especially with pump faults.

• Read the exact pen/pump instructions, prime as directed, use new needles and remove needles after pen injections. Check product/concentration and prescribed units.
• Use the product-specific meal window and the prescribed correction plan; never calculate pen doses by concentration or transfer U-200 to a syringe.
• Never share devices; rotate healthy sites. Carry low-glucose treatment and teach caregivers emergency glucagon.
• Have an injectable backup for pump failure; discuss illness/missed meals/doses and driving safety with the care team.

Dosage form / concentration

Clear/colorless solution · 100 units/mL

Presentation

3 mL single-patient pen · 300 units

Manufacturer

Eli Lilly and Company

Example NDC

0002-8799-59 · five pens

Humalog U-100: 10/3 mL vials, 3 mL cartridges/KwikPen/Junior/Tempo; U-200: 3 mL KwikPen. Admelog U-100: 10/3 mL vials and 3 mL SoloStar. Lyumjev U-100: 10 mL vial, 3 mL cartridge/KwikPen/Junior/Tempo; U-200: 3 mL KwikPen. U-100 pens/cartridges contain 300 units; U-200 pen contains 600. Verify cartridge compatibility; premixes are separate.

Unopened: 2–8°C until expiry; do not freeze, use if frozen, or expose to direct heat/light. Selected vials/pens/cartridges have a 28-day room-temperature limit (Humalog/Admelog ≤ 30°C; Lyumjev < 30°C), including unopened time. In-use vials may be refrigerated; in-use pens/cartridges must not be. Write opening/discard dates.